{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T04:00:57Z","timestamp":1770523257983,"version":"3.49.0"},"reference-count":47,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0072","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T06:39:14Z","timestamp":1718779154000},"source":"Crossref","is-referenced-by-count":6,"title":["The early diagnosis and treatment of chronic renal insufficiency"],"prefix":"10.3238","author":[{"given":"Kai-Michael","family":"Hahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Strutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"10.3238\/arztebl.m2024.0072_ref1","doi-asserted-by":"crossref","unstructured":"Kovesdy CP: Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011) 2022; 12: 7–11.","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"10.3238\/arztebl.m2024.0072_ref2","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al.: Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392: 2052–90."},{"key":"10.3238\/arztebl.m2024.0072_ref3","doi-asserted-by":"crossref","unstructured":"Fox CS, Matsushita K, Woodward M, et al.: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662–73.","DOI":"10.1016\/S0140-6736(12)61350-6"},{"key":"10.3238\/arztebl.m2024.0072_ref4","unstructured":"Hackl D, Kossack N, Schoenfelder T: [Prevalence, costs of medical treatment and modalities of dialysis-dependent chronic renal failure in Germany: comparison of dialysis care of nursing home residents and in outpatient units]. Gesundheitswesen 2021; 83: 818–28."},{"key":"10.3238\/arztebl.m2024.0072_ref5","doi-asserted-by":"crossref","unstructured":"Fioretto P, Pontremoli R: Expanding the therapy options for diabetic kidney disease. Nat Rev Nephrol 2022; 18: 78–9.","DOI":"10.1038\/s41581-021-00522-3"},{"key":"10.3238\/arztebl.m2024.0072_ref6","doi-asserted-by":"crossref","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR: Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am J Prev Cardiol 2023; 14: 100502.","DOI":"10.1016\/j.ajpc.2023.100502"},{"key":"10.3238\/arztebl.m2024.0072_ref7","unstructured":"Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The prevalence of renal failure—Results from the German Health Interview and Examination Survey for Adults, 2008–2011 (DEGS1). Dtsch Arztebl Int 2016; 113: 85–91."},{"key":"10.3238\/arztebl.m2024.0072_ref8","doi-asserted-by":"crossref","unstructured":"Zoccali C, Mallamaci F, Tripepi G, et al.: The long-term benefits of early intensive therapy in chronic diseases-the legacy effect. Clin Kidney J 2023; 16: 1917–24.","DOI":"10.1093\/ckj\/sfad186"},{"key":"10.3238\/arztebl.m2024.0072_ref9","doi-asserted-by":"crossref","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, et al.: Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med 2023; 176: 381–7.","DOI":"10.7326\/M22-2904"},{"key":"10.3238\/arztebl.m2024.0072_ref10","doi-asserted-by":"crossref","unstructured":"Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C: A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019; 96: 1048–50.","DOI":"10.1016\/j.kint.2019.07.012"},{"key":"10.3238\/arztebl.m2024.0072_ref11","doi-asserted-by":"crossref","unstructured":"Tuttle KR, Wong L, St Peter W, et al.: Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 2022; 17: 1092–103.","DOI":"10.2215\/CJN.02980322"},{"key":"10.3238\/arztebl.m2024.0072_ref12","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305.","DOI":"10.1056\/NEJMoa041031"},{"key":"10.3238\/arztebl.m2024.0072_ref13","doi-asserted-by":"crossref","unstructured":"Tangri N, Moriyama T, Schneider MP, et al.: Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open 2023; 13: e067386.","DOI":"10.1136\/bmjopen-2022-067386"},{"key":"10.3238\/arztebl.m2024.0072_ref14","doi-asserted-by":"crossref","unstructured":"Levin A, Okpechi IG, Caskey FJ, Yang CW, Tonelli M, Jha V: Perspectives on early detection of chronic kidney disease: the facts, the questions, and a proposed framework for 2023 and beyond. Kidney Int 2023; 103: 1004–8.","DOI":"10.1016\/j.kint.2023.03.009"},{"key":"10.3238\/arztebl.m2024.0072_ref15","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, et al.: The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2021; 99: 34–47."},{"key":"10.3238\/arztebl.m2024.0072_ref16","doi-asserted-by":"crossref","unstructured":"van Mil D, Kieneker LM, Evers-Roeten B, et al.: Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet 2023; 402: 1052–64.","DOI":"10.1016\/S0140-6736(23)00876-0"},{"key":"10.3238\/arztebl.m2024.0072_ref17","unstructured":"Nationale Versorgungsleitlinie Hypertonie; 2023 www.awmf.org\/service\/awmf-aktuell\/nationale-versorgungsleitlinie-hypertonie (last accessed on 23 May 2024)"},{"key":"10.3238\/arztebl.m2024.0072_ref18","doi-asserted-by":"crossref","unstructured":"Jones NR, McCormack T, Constanti M, McManus RJ: Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract 2020; 70: 90–1.","DOI":"10.3399\/bjgp20X708053"},{"key":"10.3238\/arztebl.m2024.0072_ref19","unstructured":"Nationale Versorgungsleitlinie Typ-2-Diabetes; 2023 Nationale Versorgungsleitlinie Typ 2-Diabetes Teilpublikation der Langfassung. 2nd edition Version 1, awfm.org (last accessed on 23 May 2024)."},{"key":"10.3238\/arztebl.m2024.0072_ref20","doi-asserted-by":"crossref","unstructured":"American Diabetes A: Standards of care in diabetes-2023 abridged for primary care providers. Clin Diabetes 2022; 41: 4–31.","DOI":"10.2337\/cd23-as01"},{"key":"10.3238\/arztebl.m2024.0072_ref21","doi-asserted-by":"crossref","unstructured":"de Boer IH, Khunti K, Sadusky T, et al: Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Assoziation (ADA) and kidney disease: Improving Global Outcome (KDIGO). Diab Care 2022; 45: 3075–90.","DOI":"10.2337\/dci22-0027"},{"key":"10.3238\/arztebl.m2024.0072_ref22","doi-asserted-by":"crossref","unstructured":"Levey AS, Coresh J, Balk E, et al.: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–47.","DOI":"10.7326\/0003-4819-139-2-200307150-00013"},{"key":"10.3238\/arztebl.m2024.0072_ref23","doi-asserted-by":"crossref","unstructured":"Mahmoodi BK, Matsushita K, Woodward M, et al.: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380: 1649–61.","DOI":"10.1016\/S0140-6736(12)61272-0"},{"key":"10.3238\/arztebl.m2024.0072_ref24","doi-asserted-by":"crossref","unstructured":"van der Velde M, Matsushita K, Coresh J, et al.: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341–52.","DOI":"10.1038\/ki.2010.536"},{"key":"10.3238\/arztebl.m2024.0072_ref25","unstructured":"Writing Group for the CKDPC, Grams ME, Coresh J, et al.: Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA 2023; 330: 1266–77."},{"key":"10.3238\/arztebl.m2024.0072_ref26","doi-asserted-by":"crossref","unstructured":"Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al.: Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32–5.","DOI":"10.1161\/01.CIR.0000133312.96477.48"},{"key":"10.3238\/arztebl.m2024.0072_ref27","doi-asserted-by":"crossref","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7.","DOI":"10.1161\/01.CIR.0000139860.33974.28"},{"key":"10.3238\/arztebl.m2024.0072_ref28","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436–46.","DOI":"10.1056\/NEJMoa2024816"},{"key":"10.3238\/arztebl.m2024.0072_ref29","doi-asserted-by":"crossref","unstructured":"Chertow GM, Vart P, Jongs N, et al.: Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol 2021; 32: 2352–61.","DOI":"10.1681\/ASN.2021020167"},{"key":"10.3238\/arztebl.m2024.0072_ref30","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Berger S, Gansevoort RT, Renal Life Cycle Trial I: Will SGLT2 inhibitors be effective and safe in patients with severe CKD, dialysis, or kidney transplantation. Clin J Am Soc Nephrol 2023; 18: 1500–2.","DOI":"10.2215\/CJN.0000000000000221"},{"key":"10.3238\/arztebl.m2024.0072_ref31","doi-asserted-by":"crossref","unstructured":"Group E-KC, Herrington WG, Staplin N, et al.: Empagliflozin in patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117–27.","DOI":"10.1056\/NEJMoa2204233"},{"key":"10.3238\/arztebl.m2024.0072_ref32","doi-asserted-by":"crossref","unstructured":"Rossing P, Caramori ML, Chan JCN, et al.: Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. Kidney Int 2022; 102: 990–9.","DOI":"10.1016\/j.kint.2022.06.013"},{"key":"10.3238\/arztebl.m2024.0072_ref33","unstructured":"Neues zu Nebenwirkungen von SGLT-2-Hemmern bei Diabetes mellitus Typ 2. Der Arzneimittelbrief 2016; 50: 52."},{"key":"10.3238\/arztebl.m2024.0072_ref34","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, August P, et al.: Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother 2023; 9: 183–91.","DOI":"10.1093\/ehjcvp\/pvad001"},{"key":"10.3238\/arztebl.m2024.0072_ref35","doi-asserted-by":"crossref","unstructured":"Sarafidis P, Agarwal R, Pitt B, et al.: Outcomes with finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol 2023; 18: 602–12.","DOI":"10.2215\/CJN.0000000000000149"},{"key":"10.3238\/arztebl.m2024.0072_ref36","doi-asserted-by":"crossref","unstructured":"Rossing P, Anker SD, Filippatos G, et al.: Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY Analysis. Diabetes Care 2022; 45: 2991–8.","DOI":"10.2337\/figshare.20289009"},{"key":"10.3238\/arztebl.m2024.0072_ref37","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219–29.","DOI":"10.1056\/NEJMoa2025845"},{"key":"10.3238\/arztebl.m2024.0072_ref38","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, et al.: An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci 2022; 23: 3651.","DOI":"10.3390\/ijms23073651"},{"key":"10.3238\/arztebl.m2024.0072_ref39","doi-asserted-by":"crossref","unstructured":"Dikow R, Ritz E: Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003; 18: 1993–8.","DOI":"10.1093\/ndt\/gfg253"},{"key":"10.3238\/arztebl.m2024.0072_ref40","doi-asserted-by":"crossref","unstructured":"Carney EF: Risk factors: contribution of low GFR to the global burden of disease. Nat Rev Nephrol 2015; 11: 630.","DOI":"10.1038\/nrneph.2015.160"},{"key":"10.3238\/arztebl.m2024.0072_ref41","doi-asserted-by":"crossref","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, et al.: Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. Health Care Organizations. Diabetes Care 2021; 44: 2000–9.","DOI":"10.2337\/dc20-2715"},{"key":"10.3238\/arztebl.m2024.0072_ref42","doi-asserted-by":"crossref","unstructured":"Persson F, Bain SC, Mosenzon O, et al.: Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post hoc analysis of the LEADER Trial. Diabetes Care 2021; 44: 1020–6.","DOI":"10.2337\/dc20-1622"},{"key":"10.3238\/arztebl.m2024.0072_ref43","doi-asserted-by":"crossref","unstructured":"Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754–62.","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"10.3238\/arztebl.m2024.0072_ref44","doi-asserted-by":"crossref","unstructured":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857–63.","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"10.3238\/arztebl.m2024.0072_ref45","doi-asserted-by":"crossref","unstructured":"Atkins RC, Briganti EM, Lewis JB, et al.: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281–7.","DOI":"10.1053\/j.ajkd.2004.10.019"},{"key":"10.3238\/arztebl.m2024.0072_ref46","doi-asserted-by":"crossref","unstructured":"Green JB, Mottl AK, Bakris G, et al.: Design of the combination effect of FInerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 2023; 38: 894–903.","DOI":"10.1093\/ndt\/gfac198"},{"key":"10.3238\/arztebl.m2024.0072_ref47","doi-asserted-by":"crossref","unstructured":"Tomita I, Kume S, Sugahara S et al.: SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 2020; 32: 404–19.","DOI":"10.1016\/j.cmet.2020.06.020"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T06:40:16Z","timestamp":1718779216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0072","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}